Raymond James & Associates’s NanoViricides NNVC Stock Holding History

Raymond James & Associates’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,041	Closed	-$5K	–	3682
2019 Q2	$5K	Sell	1,041 -1,988	-66%	-$10.2K	﹤0.01%	3610
2019 Q1	$16K	Hold	3,029	–	–	﹤0.01%	3544
2018 Q4	$12K	Hold	3,029	–	–	﹤0.01%	3466
2018 Q3	$22K	Hold	3,029	–	–	﹤0.01%	3540
2018 Q2	$27K	Buy	3,029 +29	+1%	+$356	﹤0.01%	3481
2018 Q1	$49K	Hold	3,000	–	–	﹤0.01%	3325
2017 Q4	$53K	Hold	3,000	–	–	﹤0.01%	3275
2017 Q3	$68K	Hold	3,000	–	–	﹤0.01%	3220
2017 Q2	$81K	Hold	3,000	–	–	﹤0.01%	3139
2017 Q1	$67K	Sell	3,000 -100	-3%	-$2.33K	﹤0.01%	3119
2016 Q4	$66K	Sell	3,100 -451	-13%	-$12K	﹤0.01%	3072
2016 Q3	$120K	Buy	+3,551	New	+$118K	﹤0.01%	2965

Other funds holding NNVC

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BCWM

Bartlett & Co Wealth Management Cincinnati, Ohio $7.99B AUM 20.76% 1-Year Est. Return

Bartlett & Co Cincinnati, Ohio $6.16B AUM 20.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Raymond James & Associates's NNVC Position: Q3 2019 in Review

Raymond James & Associates sold out of NanoViricides (NNVC) in Q3 2019, closing a stake of 1,041 shares — an estimated $5K sold.

Raymond James & Associates first reported a position in NNVC in Q3 2016 and held it in 12 quarters. The position peaked at $120K in Q3 2016. 17 funds tracked by Wall St. Rank hold NNVC as of Q3 2019.

Raymond James & Associates reported no remaining NanoViricides position as of Q3 2019 after selling out during the quarter.
Raymond James & Associates sold 1,041 NanoViricides shares in Q3 2019, an estimated $5K.
Raymond James & Associates first reported a position in NanoViricides in Q3 2016 and held it in 12 quarters.
Raymond James & Associates's NanoViricides position peaked at $120K in Q3 2016.
17 funds tracked by Wall St. Rank held NanoViricides as of Q3 2019.

Based on Raymond James & Associates's 13F filing for Q3 2019, filed 7 Nov 2019.